The UK and the European Union have formalised a new UK-EU drug cooperation deal, with the Department of Health and Social Care signing a Working Arrangement with the European Union Drugs Agency (EUDA) on 13 July 2026. The agreement, prepared entirely in English, sets out nine sections covering everything from the scope of cooperation to how disputes will be resolved if the relationship runs into difficulty.

The legal basis behind the agreement

This UK-EU drug cooperation deal did not emerge in isolation. It rests on Regulation (EU) 2023/1322 of the European Parliament and the Council, adopted on 27 June 2023, which established EUDA as a decentralised EU agency built around four interconnected functions: anticipating drug threats, alerting institutions and the public to them, responding to emerging risks, and learning from experience to refine future action.

Article 53 of that regulation requires EUDA to seek cooperation with international organisations and other bodies, including governmental and non-governmental technical bodies, and states that such cooperation must be built on formal working arrangements. This document is the product of that requirement. Before signing, EUDA’s Management Board had to adopt it and secure prior approval from the European Commission, which then authorised the agency’s Executive Director to sign. DHSC signs specifically in the field of drug risks and threats.

EUDA frames its own mission in stark terms. The agency describes today’s drug situation as complex, citing potent substances being produced, trafficked and sold at an unprecedented scale, and positions itself as a body working to keep Europe’s streets safer and save lives. Its role extends to issuing health and security alerts, sharing risk communications and knowledge, and recommending evidence-based policies to EU institutions and member states.

The seven areas of cooperation

Section 2 of the UK-EU drug cooperation deal lays out exactly where DHSC and EUDA intend to work together, and the list is broader than prevention alone. The seven named areas are:

Drug information systems, early warning systems, alerts and threat assessments come first, reflecting EUDA’s core function of spotting emerging risks before they escalate. Second is the production, processing and trafficking of illicit drugs and new psychoactive substances, covering the supply side of the drug trade directly. Third, the arrangement addresses the drivers and consequences of drug markets, a broader look at why demand and supply behave the way they do. Fourth is the production, diversion and trafficking of precursor chemicals, the raw materials used to manufacture illegal drugs. Fifth, the two sides intend to share work on relevant policies and laws. Sixth, and the area most relevant to prevention advocates, is drug prevention, treatment, social reintegration and harm reduction, grouped together as a single strand rather than broken out separately. Seventh and last is forensic and toxicological testing, the scientific work that underpins prosecutions and threat identification alike.

This list is explicitly non-exhaustive. Both sides retain scope to expand cooperation into further areas as mutually agreed.

How the two sides will actually work together

Section 3 sets out three practical modes of cooperation under the deal. The sides can exchange data, information, expertise, research findings and experiences, including through participation in joint expert meetings. They can co-produce targeted analyses within the seven scope areas already outlined. And they can facilitate study visits and missions carried out by representatives of either side.

To keep this running smoothly, Section 4 requires each side to designate a named contact person, whose role is to maintain continued dialogue and ensure the arrangement is implemented fully and efficiently over time.

Data protection sits at the centre of the deal

Given how much of this UK-EU drug cooperation deal depends on information sharing, Section 5 spells out the ground rules in some detail. Both sides acknowledge they may be legally obliged to disclose data under their own national laws or by court order, which the arrangement cannot override. Beyond that, data exchange between DHSC and EUDA is voluntary rather than mandatory, must stay confidential, and is meant to respect information security and data protection rules under applicable law.

Two further restrictions matter here. Classified information sits outside the arrangement entirely. Sensitive but non-classified information, as defined under Article 49 of the EUDA regulation, is permitted but must have limited dissemination. Perhaps most importantly for anyone concerned about civil liberties, the arrangement states directly that it is not intended to be used as a mechanism for transferring personal data between the two sides.

No money, no legal obligations

Section 6 is short but significant. The Working Arrangement creates no legal rights or obligations on either side under domestic or international law, and it creates no political or financial commitments. This UK-EU drug cooperation deal is a framework for cooperation, not a funding agreement or a treaty with binding force. Any concrete action that flows from it, joint research, information sharing, staff exchanges, would need separate action within this non-binding structure.

Safeguards against fraud and misuse of funds

Section 7 addresses financial integrity, though it only becomes relevant in scenarios where EU funds are actually disbursed through the agency. Under Article 48(3), (4) and (5) of the EUDA regulation, the European Court of Auditors retains the power to audit any grant beneficiaries, contractors or sub-contractors who receive Union funding through EUDA. Separately, the European Anti-Fraud Office, known as OLAF, can investigate, including on-the-spot checks and inspections, to establish whether fraud, corruption or other illegal activity has affected the EU’s financial interests in connection with an EUDA-funded grant or contract.

What happens if the two sides disagree

Section 8 keeps dispute resolution deliberately informal. Direct consultation between the two sides resolves any disagreement over how the arrangement is interpreted, applied or implemented. Notably, the agreement rules out escalation to any national or international tribunal, court or third party. This tracks the arrangement’s non-binding legal status established in Section 6; since it creates no enforceable rights, there is nothing for a court to adjudicate in the traditional sense.

Duration, amendment and how either side can walk away

The arrangement takes effect once both sides have signed, per Section 9. Either side can request amendments in writing at any point by mutual consent, and either side can request consultations on potential amendments at any time. Termination is straightforward: either side can end the arrangement in writing with six months’ notice. Termination does not automatically halt work already underway. Any programmes, activities or projects in progress at the point of termination continue unless both sides agree in writing to stop them.

Who signed it

Dr Lorraine Nolan, EUDA’s Executive Director, signed the arrangement for the European Union Drugs Agency. Minister Sharon Hodgson MP, Parliamentary Under-Secretary of State, signed for the Department of Health and Social Care.

What this actually means for prevention

Taken as a whole, this UK-EU drug cooperation deal is not a prevention-focused initiative dressed up in institutional language. It is a broad security and public health cooperation framework in which prevention, treatment and social reintegration sit as one of seven equally weighted strands, alongside trafficking intelligence, precursor chemical controls, drug market analysis, policy exchange and forensic science. The arrangement’s real substance lies in its architecture for sharing early warning data and threat assessments, the kind of intelligence that shapes where prevention and enforcement resources get directed on the ground, rather than in any direct funding or programme commitment.

Whether this UK-EU drug cooperation deal translates into stronger prevention outcomes in the UK depends entirely on how actively DHSC uses the channels it opens, particularly its access to EUDA’s early warning systems and joint analytical work. As a non-binding framework with no financial commitments attached, its value will be measured by what both sides actually choose to build on top of it, not by anything the document itself guarantees.

Source: euda